Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
Holding RMD?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.32Last Year’s EPS
1.88Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 25, 2018
|% Change Since: 0.52%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
ResMed demonstrated strong financial performance with double-digit revenue growth, significant profit and EPS gains, and efficient cost management. However, potential risks related to international conflicts and operating expenses were acknowledged.Company Guidance
During the ResMed Q1 2025 earnings call, the company reported robust growth metrics across its business segments, including an 11% increase in revenue, driven by strong demand for sleep health and breathing health medical devices, masks, and accessories. They achieved a 27% growth in operating profit and a 34% increase in earnings per share, reflecting disciplined investments in SG&A and R&D. The company also highlighted a 10% growth in global device sales, supported by the strong performance of the AirSense 10 and AirSense 11 platforms, and an 11% growth in masks and accessories, attributed to new patient activations and ReSupply programs. ResMed's gross margin improved by 320 basis points to 59.2%, and the company maintained a solid liquidity position with $1.5 billion available under its revolver facility. The effective tax rate was 19.2%, with expectations for it to remain between 19% and 21% for fiscal year 2025. ResMed also announced plans to purchase approximately $75 million in shares per quarter through the remainder of fiscal year 2025.Strong Revenue Growth
ResMed reported an 11% increase in revenue for Q1 FY2025, driven by strong demand for sleep health and breathing health medical devices and masks.
Double-Digit Growth in Devices and Masks
ResMed achieved 10% growth in global device sales and 11% growth in masks and accessories sales year-over-year.
Operating Profit and EPS Growth
Operating profit increased by 27%, and earnings per share grew by 34% in Q1 FY2025.
Product Innovations
The upcoming launch of the AirTouch N30i mask and continued expansion of AirSense 11 platform were highlighted as key growth drivers.
Residential Care Software Growth
Residential care software revenue increased by 12%, supported by MEDIFOX DAN and strong HME software performance.
Gross Margin Improvement
Gross margin increased by 320 basis points to 59.2%, driven by manufacturing efficiencies and price improvements.
---
RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 24, 2024 | $238.53 | $255.52 | +7.12% |
| Aug 01, 2024 | $213.59 | $222.62 | +4.23% |
| Apr 25, 2024 | $182.18 | $216.59 | +18.89% |
| Jan 24, 2024 | $170.19 | $184.63 | +8.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Resmed (RMD) report earnings?
Resmed (RMD) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Resmed (RMD) earnings time?
Resmed (RMD) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RMD EPS forecast?
RMD EPS forecast for the fiscal quarter 2025 (Q2) is 2.32.
---